Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase Ib Trial of E39 and J65 Vaccines in Breast and Ovarian Cancer
NCT02019524Phase 1Completed
- Start
- Sep 2013
- Primary completion
- Dec 2016
- Modality
- Peptides, Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 1, randomised, single-blind trial of folate binding protein E39 and J65 in breast cancer and ovarian cancer (3 arms). Primary endpoint: Primary vaccination strategy immunologic recognition. Started Sep 2013; status: completed.
02
Drugs
folate binding protein E39J65
03
Conditions
breast cancerovarian cancer
Beyond the preview
Go deeper on NCT02019524.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02019524.